Corvus Pharmaceuticals (NASDAQ:CRVS) Issues Earnings Results, Misses Expectations By $0.06 EPS

Corvus Pharmaceuticals (NASDAQ:CRVS) announced its earnings results on Tuesday. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.06), Zacks reports.

Corvus Pharmaceuticals Trading Down 7.5 %

Corvus Pharmaceuticals stock opened at $3.93 on Wednesday. The company has a market capitalization of $252.53 million, a P/E ratio of -4.23 and a beta of 0.91. Corvus Pharmaceuticals has a 1-year low of $1.30 and a 1-year high of $10.00. The firm’s fifty day simple moving average is $4.70 and its 200-day simple moving average is $6.09.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $11.00 target price on shares of Corvus Pharmaceuticals in a research report on Tuesday, January 14th. One analyst has rated the stock with a sell rating, four have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $12.38.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.